05/05/2020
The COVID-19 pandemic is necessitating extraordinary efforts by all Americans to reduce the spread of the virus and minimize the loss of life. As we continue through this first wave of the pandemic, we are already witnessing the broad effects this crisis is having not only on the health of individuals and families, but also on their economic well-being. In light of these concerns, we urge HHS to reconsider the proposed provision in the 2021 Notice of Benefit Payment Parameters that grants issuers the discretion not to count drug copayment assistance towards a member’s annual cost sharing, regardless of whether a generic exists.